STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

A recent analysis of cancer drug approvals by European regulators reveals that a majority of new medicines authorized over a four-year period fail to demonstrate high clinical benefit. Out of 97 approved indications, only 31% were found to provide significant clinical advantages to patients.